Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10311843" target="_blank" >RIV/00216208:11110/15:10311843 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10311843

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s12185-015-1847-4" target="_blank" >http://dx.doi.org/10.1007/s12185-015-1847-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s12185-015-1847-4" target="_blank" >10.1007/s12185-015-1847-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas

Popis výsledku v původním jazyce

The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could ma

Název v anglickém jazyce

Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas

Popis výsledku anglicky

The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could ma

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Hematology

ISSN

0925-5710

e-ISSN

—

Svazek periodika

102

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

JP - Japonsko

Počet stran výsledku

10

Strana od-do

441-450

Kód UT WoS článku

000362673700009

EID výsledku v databázi Scopus

2-s2.0-84951569763